<?xml version="1.0" encoding="iso-8859-1" standalone="no"?>
<!DOCTYPE GmsArticle SYSTEM "http://www.egms.de/dtd/2.0.34/GmsArticle.dtd">
<GmsArticle xmlns:xlink="http://www.w3.org/1999/xlink">
  <MetaData>
    <Identifier>zma001664</Identifier>
    <IdentifierDoi>10.3205/zma001664</IdentifierDoi>
    <IdentifierUrn>urn:nbn:de:0183-zma0016647</IdentifierUrn>
    <ArticleType language="en">article</ArticleType>
    <ArticleType language="de">Artikel</ArticleType>
    <TitleGroup>
      <Title language="en">Neuroenhancement and mental health in students from four faculties &#8211; a cross-sectional questionnaire study </Title>
      <TitleTranslated language="de">Neuroenhancement und psychische Gesundheit bei Studierenden aus vier Fachbereichen &#8211; eine Fragebogen-Querschnittsstudie </TitleTranslated>
    </TitleGroup>
    <CreatorList>
      <Creator>
        <PersonNames>
          <Lastname>Hajduk</Lastname>
          <LastnameHeading>Hajduk</LastnameHeading>
          <Firstname>Maurice</Firstname>
          <Initials>M</Initials>
        </PersonNames>
        <Address language="en">
          <Affiliation>University Medical Centre W&#252;rzburg, Institute of General Practice, W&#252;rzburg, Germany</Affiliation>
        </Address>
        <Address language="de">
          <Affiliation>Universit&#228;tsklinikum W&#252;rzburg, Institut f&#252;r Allgemeinmedizin, W&#252;rzburg, Deutschland</Affiliation>
        </Address>
        <Email>maurice.hajduk&#64;stud-mail.uni-wuerzburg.de</Email>
        <Creatorrole corresponding="no" presenting="no">author</Creatorrole>
      </Creator>
      <Creator>
        <PersonNames>
          <Lastname>Tiedemann</Lastname>
          <LastnameHeading>Tiedemann</LastnameHeading>
          <Firstname>Elena</Firstname>
          <Initials>E</Initials>
        </PersonNames>
        <Address language="en">
          <Affiliation>University Medical Centre W&#252;rzburg, Institute of General Practice, W&#252;rzburg, Germany</Affiliation>
        </Address>
        <Address language="de">
          <Affiliation>Universit&#228;tsklinikum W&#252;rzburg, Institut f&#252;r Allgemeinmedizin, W&#252;rzburg, Deutschland</Affiliation>
        </Address>
        <Email>tiedemann&#95;e&#64;ukw.de</Email>
        <Creatorrole corresponding="no" presenting="no">author</Creatorrole>
      </Creator>
      <Creator>
        <PersonNames>
          <Lastname>Romanos</Lastname>
          <LastnameHeading>Romanos</LastnameHeading>
          <Firstname>Marcel</Firstname>
          <Initials>M</Initials>
        </PersonNames>
        <Address language="en">
          <Affiliation>University Medical Centre W&#252;rzburg, Clinic and Polyclinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, W&#252;rzburg, Germany</Affiliation>
        </Address>
        <Address language="de">
          <Affiliation>Universit&#228;tsklinikum W&#252;rzburg, Klinik und Poliklinik f&#252;r Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, W&#252;rzburg, Deutschland</Affiliation>
        </Address>
        <Email>romanos&#95;M&#64;ukw.de</Email>
        <Creatorrole corresponding="no" presenting="no">author</Creatorrole>
      </Creator>
      <Creator>
        <PersonNames>
          <Lastname>Simmenroth</Lastname>
          <LastnameHeading>Simmenroth</LastnameHeading>
          <Firstname>Anne</Firstname>
          <Initials>A</Initials>
          <AcademicTitle>Prof. Dr.</AcademicTitle>
        </PersonNames>
        <Address language="en">University Medical Centre W&#252;rzburg, Institute of General Practice, Josef-Schneider-Str. 2&#47;D7, D-97080 W&#252;rzburg, Germany<Affiliation>University Medical Centre W&#252;rzburg, Institute of General Practice, W&#252;rzburg, Germany</Affiliation></Address>
        <Address language="de">Universit&#228;tsklinikum W&#252;rzburg, Institut f&#252;r Allgemeinmedizin, Josef-Schneider-Str. 2&#47;D7, 97080 W&#252;rzburg, Deutschland<Affiliation>Universit&#228;tsklinikum W&#252;rzburg, Institut f&#252;r Allgemeinmedizin, W&#252;rzburg, Deutschland</Affiliation></Address>
        <Email>simmenroth&#95;a&#64;ukw.de</Email>
        <Creatorrole corresponding="yes" presenting="no">author</Creatorrole>
      </Creator>
    </CreatorList>
    <PublisherList>
      <Publisher>
        <Corporation>
          <Corporatename>German Medical Science GMS Publishing House</Corporatename>
        </Corporation>
        <Address>D&#252;sseldorf</Address>
      </Publisher>
    </PublisherList>
    <SubjectGroup>
      <SubjectheadingDDB>610</SubjectheadingDDB>
      <Keyword language="en">medical student</Keyword>
      <Keyword language="en">neuroenhancement</Keyword>
      <Keyword language="en">cognitive enhancement</Keyword>
      <Keyword language="en">brain doping</Keyword>
      <Keyword language="en">smoking</Keyword>
      <Keyword language="en">alcohol</Keyword>
      <Keyword language="de">Medizinstudent</Keyword>
      <Keyword language="de">Neuroenhancement</Keyword>
      <Keyword language="de">kognitives Enhancement</Keyword>
      <Keyword language="de">Gehirn-Doping</Keyword>
      <Keyword language="de">Rauchen</Keyword>
      <Keyword language="de">Alkohol</Keyword>
      <SectionHeading language="en">mental health</SectionHeading>
      <SectionHeading language="de">Psychische Gesundheit</SectionHeading>
    </SubjectGroup>
    <DateReceived>20230822</DateReceived>
    <DateRevised>20231031</DateRevised>
    <DateAccepted>20231129</DateAccepted>
    <DatePublishedList>
      
    <DatePublished>20240215</DatePublished></DatePublishedList>
    <Language>engl</Language>
    <LanguageTranslation>germ</LanguageTranslation>
    <License license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
      <AltText language="en">This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License.</AltText>
      <AltText language="de">Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung).</AltText>
    </License>
    <SourceGroup>
      <Journal>
        <ISSN>2366-5017</ISSN>
        <Volume>41</Volume>
        <Issue>1</Issue>
        <JournalTitle>GMS Journal for Medical Education</JournalTitle>
        <JournalTitleAbbr>GMS J Med Educ</JournalTitleAbbr>
      </Journal>
    </SourceGroup>
    <ArticleNo>9</ArticleNo>
  </MetaData>
  <OrigData>
    <Abstract language="de" linked="yes"><Pgraph><Mark1>Hintergrund: </Mark1>W&#228;hrend des Studiums stehen Studierende vor gro&#223;en Herausforderungen: Leistungsanforderungen seitens der Hochschulen, Konkurrenzerleben, Pr&#252;fungsangst und die neu gewonnene Selbstst&#228;ndigkeit k&#246;nnen zu Stresserleben, Angst und Depressivit&#228;t f&#252;hren. Die vorliegende Studie untersucht, inwieweit psychisch st&#228;rker belastete Studierende h&#228;ufiger Neuroenhancement (NE) nutzen.</Pgraph><Pgraph><Mark1>Zielsetzung: </Mark1>Ermittlung der H&#228;ufigkeit von NE, Alkohol- und Tabakkonsum unter Studierenden sowie Untersuchung der Zusammenh&#228;nge zwischen NE und ADHS, Angst, Depressivit&#228;t und Stresserleben.</Pgraph><Pgraph><Mark1>Methodik: </Mark1>Im Fr&#252;hjahr 2021 wurde eine anonyme Online-Querschnittsbefragung bei Studierenden der Medizin, Zahnmedizin, Wirtschaftswissenschaften und -Informatik an W&#252;rzburger Hochschulen durchgef&#252;hrt. Der Survey umfasste die Instrumente ASRS (ADHS), PSS-10 (Stress), PHQ-4 (Depressions- und Angstsymptome) und AUDIT-C (riskanter Alkoholkonsum), sowie Fragen zu Konsumverhalten, Vorwissen und Gr&#252;nden f&#252;r NE.</Pgraph><Pgraph><Mark1>Ergebnisse: </Mark1>1010 von 5564 Studierenden nahmen am Survey teil (18.2&#37;). Davon gaben 12.4&#37; NE f&#252;r den Zeitraum des Studiums an. NE wurde insbesondere w&#228;hrend der Pr&#252;fungsvorbereitung zur Leistungssteigerung und&#47;oder zur emotionalen Regulation eingesetzt, am h&#228;ufigsten durch Koffeintabletten, Cannabis und Methylphenidat. NE war assoziiert mit riskantem Alkohol- bzw. Tabakkonsum, im geringeren Ausma&#223; mit ADHS-Symptomen und Stresserleben.</Pgraph><Pgraph>Schlussfolgerung: Bei Studierenden besteht ein Risiko f&#252;r Substanzmissbrauch und NE. Wirksame Stressbew&#228;ltigungs- und Pr&#228;ventionsans&#228;tze sowie niederschwellige Hilfsangebote sind erforderlich, um Studierende mit Risikoprofil zu erkennen und zu unterst&#252;tzen.</Pgraph></Abstract>
    <Abstract language="en" linked="yes"><Pgraph><Mark1>Background: </Mark1>Students face great challenges at the beginning of and during their studies. Competitive experience, exam anxiety, and especially the new performance requirements often cause test anxiety and stressful experiences. The extent of substance use in terms of neuroenhancement (NE) is unclear. Evidence shows associations between NE, increased stress levels, and mental health.</Pgraph><Pgraph><Mark1>Objectives: </Mark1>We aim to determine the prevalence of NE and alcohol and tobacco use among college students. We also investigate the associations between NE and ADHD, anxiety, depression, and stress experience.</Pgraph><Pgraph><Mark1>Methods: </Mark1>In spring 2021, an anonymous online cross-sectional survey was conducted among students of medicine, dentistry, business economics, and business informatics in W&#252;rzburg. The survey included the instruments ASRS (ADHD), PSS-10 (stress), PHQ-4 (depression and anxiety), and AUDIT-C (alcohol comsumption), as well as questions about consumption patterns, prior knowledge, and reasons for NE.</Pgraph><Pgraph><Mark1>Results:</Mark1> Of the 5564 students who were invited to participate, 1010 completed the questionnaire (18.2&#37;). Of these, 12.4&#37; indicated NE for the studied period. NE was used in particular during preparations for exams, to enhance performance, and&#47;or to regulate emotions, most commonly through caffeine tablets, cannabis, and methylphenidate. NE was associated with risky use of alcohol or tobacco, and to a lesser extent with ADHD symptoms and stress experience.</Pgraph><Pgraph>Conclusions: Students are at risk of substance abuse and NE. Effective stress management and prevention approaches as well as low-threshold services are needed to identify and support students with risk profiles.</Pgraph></Abstract>
    <TextBlock language="en" linked="yes" name="1. Background">
      <MainHeadline>1. Background</MainHeadline><Pgraph>Students face major challenges at the beginning of their studies: Many leave home for the first time, reorient themselves socially, and may have to deal with exam anxiety and stress. In order to enable themselves to face these challenges, students consume alcohol, nicotine, and illegal (e.g. cannabis, speed, or cocaine) and prescription substances (e.g. methylphenidate, modafinil, or beta-blockers) <TextLink reference="1"></TextLink>, <TextLink reference="2"></TextLink> to learn or relax more efficiently <TextLink reference="3"></TextLink>. We refer below with the term &#8220;neuroenhancement&#8221; (NE) to the use of substances with the aim of coping with the challenges of studying. The substances in these cases are not prescribed on the basis of a medical diagnosis. Depending on the substances that were investigated, the prevalence of NE in European student populations ranges from &#60;1&#37; to 22.5&#37; <TextLink reference="4"></TextLink>, <TextLink reference="5"></TextLink>, <TextLink reference="6"></TextLink>, <TextLink reference="7"></TextLink>. </Pgraph><Pgraph>While NE in healthy individuals is seen as an abusive substance use to enhance personal performance, there is increasing evidence of a link between mental disorders and NE. For example, NE with methylphenidate has been described as a self-medication strategy in people with undiagnosed symptoms of attention-deficit hyperactivity disorder (ADHD) <TextLink reference="6"></TextLink>, <TextLink reference="8"></TextLink>, <TextLink reference="9"></TextLink>. Further findings suggest an association with increased stress levels <TextLink reference="10"></TextLink>, <TextLink reference="11"></TextLink> and anxiety <TextLink reference="6"></TextLink>, <TextLink reference="11"></TextLink>, <TextLink reference="12"></TextLink>, whereas the relation with depression is unclear <TextLink reference="8"></TextLink>, <TextLink reference="11"></TextLink>, <TextLink reference="12"></TextLink>. Increased alcohol consumption and smoking also appear to be associated with NE <TextLink reference="2"></TextLink>, <TextLink reference="12"></TextLink>, <TextLink reference="13"></TextLink>, and it may indicate a generally increased propensity to substance use <TextLink reference="13"></TextLink>.</Pgraph><Pgraph>Because consistent data on NE among students are lacking, especially among medical students, we conducted an anonymous survey to determine the prevalence of NE, alcohol, and tobacco use. In addition, we investigated the relation between NE and mental health, in particular, symptoms of ADHD, anxiety, depression, and stress.</Pgraph></TextBlock>
    <TextBlock language="de" linked="yes" name="1. Hintergrund">
      <MainHeadline>1. Hintergrund</MainHeadline><Pgraph>Zu Beginn des Studiums stehen Studierende vor gro&#223;en Herausforderungen: Viele verlassen erstmals das Elternhaus, orientieren sich sozial neu und m&#252;ssen ggf. mit Pr&#252;fungsangst und Stress umgehen. Um diese Herausforderungen zu kompensieren, konsumieren Studierende Alkohol, Nikotin sowie illegale (z. B. Cannabis, Speed, Kokain) und verschreibungspflichtige Substanzen (z. B. Methylphenidat, Modafinil, Betablocker) <TextLink reference="1"></TextLink>, <TextLink reference="2"></TextLink>, z. B. um effizienter lernen oder entspannen zu k&#246;nnen <TextLink reference="3"></TextLink>. Die Einnahme von Substanzen zur Bew&#228;ltigung der Herausforderung im Studium, ohne dass diese Substanzen aufgrund einer &#228;rztlichen Diagnose verschrieben wurden, wird im Folgenden als Neuroenhancement (NE) bezeichnet. F&#252;r europ&#228;ische Studierendenkollektive finden sich, abh&#228;ngig von den beforschten Substanzen, Pr&#228;valenzen f&#252;r NE zwischen &#60;1&#37; und 22.5&#37; <TextLink reference="4"></TextLink>, <TextLink reference="5"></TextLink>, <TextLink reference="6"></TextLink>, <TextLink reference="7"></TextLink>. </Pgraph><Pgraph>W&#228;hrend NE bei gesunden Personen als ein missbr&#228;uchlicher Substanzkonsum zur Leistungssteigerung angesehen wird, gibt es vermehrt Hinweise auf einen Zusammenhang zwischen psychischen St&#246;rungen und NE. So wurde z. B. NE mit Methylphenidat bei Personen mit nicht diagnostizierten Symptomen der Aufmerksamkeitsdefizit-&#47;Hyperaktivit&#228;tsst&#246;rung (ADHS) als Strategie der &#8222;Selbstmedikation&#8220; beschrieben <TextLink reference="6"></TextLink>, <TextLink reference="8"></TextLink>, <TextLink reference="9"></TextLink>. Weitere Befunde legen eine Assoziation mit erh&#246;htem Stresslevel <TextLink reference="10"></TextLink>, <TextLink reference="11"></TextLink> und Angst <TextLink reference="6"></TextLink>, <TextLink reference="11"></TextLink>, <TextLink reference="12"></TextLink> nahe, wohingegen der Zusammenhang mit Depressivit&#228;t unklar ist <TextLink reference="8"></TextLink>, <TextLink reference="11"></TextLink>, <TextLink reference="12"></TextLink>. Erh&#246;hter Alkoholkonsum und Rauchen scheinen ebenfalls mit NE assoziiert zu sein <TextLink reference="2"></TextLink>, <TextLink reference="12"></TextLink>, <TextLink reference="13"></TextLink>, was ein Hinweis auf eine generell erh&#246;hte Neigung zu Substanzkonsum darstellen k&#246;nnte <TextLink reference="13"></TextLink>. </Pgraph><Pgraph>Angesichts des Fehlens von konsistenten Daten &#252;ber NE bei Studierenden &#8211; insbesondere bei Medizinstudierenden &#8211; wurde ein anonymer Survey durchgef&#252;hrt, um die Pr&#228;valenz von NE, Alkohol- und Tabakkonsum zu ermitteln. Dar&#252;ber hinaus sollten die Zusammenh&#228;nge zwischen NE und psychischer Gesundheit, insbesondere Symptomen von ADHS, Angst, Depressivit&#228;t und Stresserleben, untersucht werden.</Pgraph></TextBlock>
    <TextBlock language="en" linked="yes" name="2. Methods">
      <MainHeadline>2. Methods</MainHeadline><SubHeadline>2.1. Study design and sample</SubHeadline><Pgraph>In the winter semester 2020&#47;21, we conducted an anonymous online cross-sectional survey to which we electronically invited a total of 5564 students. They were students from the Faculty of Medicine and Dentistry at the Julius-Maximilians-Universit&#228;t W&#252;rzburg (n&#61;2764) and the Faculty of Business Informatics and Economics at the W&#252;rzburg&#47;Schweinfurt University of Applied Sciences (n&#61;2800). The students at the university of applied sciences were selected to compensate for the high proportion of women studying medicine.</Pgraph><SubHeadline>2.2. Questionnaire</SubHeadline><Pgraph>The questionnaire consisted of 53 closed questions. No German-language validated instruments are available for the assessment of NE. The questions on NE were therefore formulated based on Middendorf et al. <TextLink reference="14"></TextLink>. The questionnaire contained a brief definition of NE and a list of substances we categorise as NE in this study (methylphenidate, modafinil, dexamphetamine, atomoxetine, beta-blockers, antidepressants, anti-dementia drugs, caffeine tablets, cocaine, MDMA (ecstasy), amphetamines (speed), and cannabis). In addition, knowledge about NE and its use by fellow students, the prescription of one of the substances mentioned, and personal NE experiences during the study period were each asked dichotomously (yes&#47;no). If the answer was yes, all substances that were used could be selected, and the motive for taking each substance could be specified (e.g. to increase concentration or to calm down). The deviation from a prescribed medication was recorded in a separate question (yes&#47;no). The questionnaire concluded with a closed item to record tobacco consumption. The students were classified as smokers if they reported &#8220;daily&#8221; or &#8220;occasional&#8221; smoking.</Pgraph><Pgraph>The following validated screening instruments were used: </Pgraph><Pgraph><UnorderedList><ListItem level="1">ADHD: ADHD Self-Report Scale V1.1 Screener (ASRS-V1 <TextLink reference="15"></TextLink>)</ListItem><ListItem level="1">Stress: Perceived Stress Scale (PSS-10 <TextLink reference="16"></TextLink>)</ListItem><ListItem level="1">Depression and anxiety symptoms: Patient Health Questionnaire-4 consisting of GAD-2 and PHQ-2 (PHQ-4 <TextLink reference="17"></TextLink>)</ListItem><ListItem level="1">Risky alcohol consumption: Alcohol Use Disorders Identification Test-Consumption (AUDIT-C <TextLink reference="18"></TextLink>)</ListItem></UnorderedList></Pgraph><SubHeadline>2.3. Data collection</SubHeadline><Pgraph>The questionnaire was created electronically using EvaSys<Superscript>&#174;</Superscript> 7.1. A direct link was distributed by email by the responsible deans of studies and via the student councils. It was aimed at all students of human medicine and dentistry (university) and at students of business informatics and economics (university of applied sciences). The link was active between 20 January 2021 and 9 March 2021. Students were reminded of the survey at least once via WhatsApp or Facebook groups. To increase the response rate, there was the opportunity to take part in a prize draw for cinema vouchers via a separate window after completing the questionnaire. The survey was also advertised through notices in the university hospital. The data collection was completely anonymous.</Pgraph><SubHeadline>2.4. Ethics, data management, and data protection</SubHeadline><Pgraph>A positive vote from the Ethics Committee of the Medical Faculty of the University of W&#252;rzburg (No. 2020050502) has been received. The security, anonymity, and legal compliance of the questionnaire and data management were confirmed by the data protection officer of the University Hospital of W&#252;rzburg.</Pgraph><SubHeadline>2.5. Data analysis</SubHeadline><Pgraph>The characteristics of the participants were analysed descriptively by subject with regard to age, semester of study, and NE, provided that this information was available on the evaluated variable (no case exclusion). For data protection regulations, it was not possible to survey the gender of the students because individuals might be identified in small subgroups (e.g. minor subject or third-gender category). </Pgraph><Pgraph>If cut-off values are established for the screening instruments, the results were evaluated using these cut-off values:</Pgraph><Pgraph><UnorderedList><ListItem level="1">ADHD: four or more positive screening items (item 1-3: &#8805;2 points, item 4-6: &#8805;3 points) in the ASRS-V1.1 or current ADHD diagnosis</ListItem><ListItem level="1">Depression symptoms: PHQ-2: &#8805;3 points</ListItem><ListItem level="1">Anxiety symptoms: GAD-2: &#8805;3 points</ListItem><ListItem level="1">Risky alcohol consumption: AUDIT-C: &#8805;4 points</ListItem></UnorderedList></Pgraph><Pgraph>Correlations were calculated using the Pearson correlation coefficient. To investigate relations between screening results and NE, a binomial logistic regression model was calculated for each instrument. Only data sets that were complete for ASRS, PSS-10, PHQ-4, AUDIT-C, and tobacco use were used (listwise case exclusion). All data were analysed with SPSS version 26.0, and p-values &#60;0.05 were considered statistically significant.</Pgraph></TextBlock>
    <TextBlock language="de" linked="yes" name="2. Methodik">
      <MainHeadline>2. Methodik</MainHeadline><SubHeadline>2.1. Studiendesign und Stichprobe</SubHeadline><Pgraph>Im Wintersemester 2020&#47;21 wurde eine anonyme Online-Querschnittsbefragung durchgef&#252;hrt, zu der insgesamt 5564 Studierende elektronisch eingeladen wurden. Diese setzten sich zusammen aus Studierenden der Medizinischen und Zahnmedizinischen Fakult&#228;t der Julius-Maximilians-Universit&#228;t W&#252;rzburg (n&#61;2764) und der Fakult&#228;t f&#252;r Wirtschaftsinformatik und Wirtschaftswissenschaften der Fachhochschule W&#252;rzburg&#47;Schweinfurt (n&#61;2800). Die F&#228;cher der Fachhochschule wurden ausgew&#228;hlt, um den hohen Frauenanteil im Medizinstudium auszugleichen.</Pgraph><SubHeadline>2.2. Fragebogen</SubHeadline><Pgraph>Der Fragebogen bestand aus 53 geschlossenen Fragen. Da es keine deutschsprachigen validierten Instrumente zur Erfassung von NE gibt, wurden die Fragen zu NE in Anlehnung an Middendorf et al. formuliert <TextLink reference="14"></TextLink>. Der Fragebogen enthielt eine kurze Definition von NE und eine Auflistung der Substanzen, die in dieser Studie als NE kategorisiert wurden (Methylphenidat, Modafinil, Dexamphetamin, Atomoxetin, Betablocker, Antidepressiva, Antidementiva, Koffeintabletten, Kokain, MDMA (Ecstasy), Amphetamine (Speed), Cannabis). Au&#223;erdem wurde das Wissen &#252;ber NE und dessen Verwendung durch Kommiliton&#42;innen, die Verschreibung einer der genannten Substanzen, und eigene NE-Erfahrungen w&#228;hrend der Studienzeit jeweils dichotom (ja&#47;nein) abgefragt. Wenn eigenes NE bejaht wurde, konnten alle verwendeten Substanzen ausgew&#228;hlt und f&#252;r jede Substanz das Motiv der Einnahme spezifiziert werden (z. B. Steigerung der Konzentration, zur Beruhigung). Die Abweichung von einer verordneten Medikation wurde in einer separaten Frage erfasst (ja&#47;nein). Der Fragebogen schloss mit einem geschlossenen Item zur Erfassung des Tabakkonsums ab. Als Rauchende wurden Personen klassifiziert, die &#8222;t&#228;gliches&#8220; oder &#8222;gelegentliches&#8220; Rauchen angaben.</Pgraph><Pgraph>Folgende validierte Screeninginstrumente wurden genutzt: </Pgraph><Pgraph><UnorderedList><ListItem level="1">ADHS: ADHD Self-Report Scale V1.1 Screener (ASRS-V1 <TextLink reference="15"></TextLink>)</ListItem><ListItem level="1">Stress: Perceived Stress Scale (PSS-10 <TextLink reference="16"></TextLink>)</ListItem><ListItem level="1">Depressions- und Angstsymptome: Patient Health Questionnaire-4 bestehend aus GAD-2 und PHQ-2 (PHQ-4 <TextLink reference="17"></TextLink>)</ListItem><ListItem level="1">Riskanter Alkoholkonsum: Alcohol Use Disorders Identification Test-Consumption (AUDIT-C <TextLink reference="18"></TextLink>) </ListItem></UnorderedList></Pgraph><SubHeadline>2.3. Datenerhebung</SubHeadline><Pgraph>Der Bogen wurde elektronisch mit EvaSys<Superscript>&#174;</Superscript> 7.1 erstellt. Ein direkter Link wurde per Mail von den zust&#228;ndigen Studiendekanaten und &#252;ber die Fachschaften verbreitet und richtete sich an alle Studierende der F&#228;cher Human- bzw. Zahnmedizin (Universit&#228;t) sowie Wirtschaftsinformatik bzw. Wirtschaftswissenschaften (Fachhochschule). Der Link war zwischen dem 20.01.2021 und dem 09.03.2021 aktiv. Studierende wurden mindestens einmal an die Umfrage &#252;ber WhatsApp- oder Facebook-Gruppen erinnert. Zur Steigerung der Antwortrate bestand nach Bearbeitung des Fragebogens die M&#246;glichkeit mittels eines separaten Fensters an der Verlosung von Kinogutscheinen teilzunehmen. Zus&#228;tzlich wurde die Befragung durch Aush&#228;nge in der Uniklinik beworben. Die Datenerhebung erfolgte vollst&#228;ndig anonym.</Pgraph><SubHeadline>2.4. Ethik, Datenmanagement, und Datenschutz </SubHeadline><Pgraph>Ein positives Votum der Ethikkommission der Medizinischen Fakult&#228;t der Universit&#228;t W&#252;rzburg (Nr. 2020050502) liegt vor. Fragebogen und Datenverwaltung wurden durch den Datenschutzbeauftragten des Universit&#228;tsklinikums W&#252;rzburg auf Sicherheit, Anonymit&#228;t und Rechtskonformit&#228;t gepr&#252;ft. </Pgraph><SubHeadline>2.5. Datenanalyse</SubHeadline><Pgraph>Die Charakteristika der Teilnehmenden wurden bez&#252;glich Alter, Studiensemester und NE deskriptiv nach Studienfach analysiert, sofern Angaben auf der ausgewerteten Variable vorhanden waren (kein Fallausschluss). Die Erhebung des Geschlechts der Studierenden war aufgrund der nicht auszuschlie&#223;enden Identifizierbarkeit einzelner Personen in kleinen Subgruppen (z.B. kleines Studienfach, dritte Geschlechtskategorie) durch Datenschutzbestimmungen nicht m&#246;glich. </Pgraph><Pgraph>Sofern Cut-Off Werte f&#252;r die Screeninginstrumente etabliert sind, erfolgte die Auswertung der Ergebnisse anhand dieser Cut-Off-Werte:</Pgraph><Pgraph><UnorderedList><ListItem level="1">ADHS: 4 oder mehr positive Screening-Items (Item 1-3: &#8805;2 Punkte, Item 4-6: &#8805;3 Punkte) im ASRS-V1.1 oder aktuelle ADHS-Diagnose</ListItem><ListItem level="1">Depressionssymptome: PHQ-2: &#8805;3 Punkte</ListItem><ListItem level="1">Angstsymptome: GAD-2: &#8805;3 Punkte</ListItem><ListItem level="1">Riskanter Alkoholkonsum: AUDIT-C: &#8805;4 Punkte</ListItem></UnorderedList></Pgraph><Pgraph>Korrelationen wurden mit dem Pearson-Korrelationskoeffizienten berechnet. Um Zusammenh&#228;nge zwischen Screeningergebnissen und NE zu untersuchen, wurde f&#252;r jedes Instrument ein binomiales logistisches Regressionsmodell berechnet. Daf&#252;r wurden nur Datens&#228;tze verwendet, die f&#252;r ASRS, PSS-10, PHQ-4, AUDIT-C und Tabakkonsum vollst&#228;ndig waren (listenweiser Fallausschluss). Alle Daten wurden mit SPSS Version 26.0 analysiert und p-Werte &#60;0.05 als statistisch signifikant angesehen.</Pgraph></TextBlock>
    <TextBlock language="en" linked="yes" name="3. Results">
      <MainHeadline>3. Results</MainHeadline><SubHeadline>3.1. Sample description</SubHeadline><Pgraph>Of the 5564 students we surveyed, 1010 completed the questionnaire (response rate: 18.2&#37;). The respective proportion of respondents is shown in table 1 <ImgLink imgNo="1" imgType="table"/>. The largest group (n&#61;594, 61.9&#37;) consisted of 21-25-year-old students (born 1996-2000). They were followed in descending order of frequency by those born 1991-1995 (n&#61;225, 23.5&#37;), &#62;2001 (n&#61;82, 8.6&#37;), and &#60;1990 (n&#61;58, 6&#37;). The age distribution varied only slightly across the departments. The number of students in the first to fourth semester (n&#61;394, 39&#37;) did not differ significantly from those in the fifth to eighth semester (n&#61;406, 40.2&#37;). At the time of the survey, 20.8&#37; of the participants (n&#61;210) had studied for more than eight semesters.</Pgraph><SubHeadline>3.2. Neuroenhancement</SubHeadline><Pgraph>In the 1010 completed questionnaires, 125 students affirmed that they had practiced NE during their studies. This places the prevalence of NE during studies at 12.4&#37;. The prevalence of NE during studies, knowledge about NE, and the proportion of fellow students who are known to use substances for NE are shown in table 2 <ImgLink imgNo="2" imgType="table"/> by subject.</Pgraph><Pgraph>One hundred and twenty-four students provided information on the regularity of NE: About half of the students (n&#61;61) denied regular use in the last three months. Almost daily use was reported by 11.3&#37; (n&#61;14), weekly use by 15.3&#37; (n&#61;19), and monthly use by 9.7&#37; (n&#61;12) of the students. </Pgraph><Pgraph>Almost half of the students with NE experience reported NE in the last 30 days (n&#61;57). For n&#61;25 (20.3&#37;), NE had been used between 30 days and a year ago, for a third, at least a year had passed since the last use. The most common reason given for NE was exam preparation (n&#61;102, 10.1&#37; of the total sample; 81.6&#37; of the users); NE was less common during the semester (n&#61;50, 5&#37; of the total sample; 40&#37; of the users).</Pgraph><Pgraph>A doctor&#8217;s prescription for one of the substances in the questionnaire had been obtained by 4.7&#37; (n&#61;47) of the participants. Of these, 17.0&#37; (n&#61;8) had deviated from the prescribed dose for NE purposes. When we included deviations from the prescribed dose as NE, the prevalence of NE increased from 12.4&#37; to 12.7&#37; (n&#61;128).</Pgraph><Pgraph>Caffeine tablets, cannabis, and methylphenidate were most frequently used for NE (see figure 1 <ImgLink imgNo="1" imgType="figure"/>). Caffeine tablets, methylphenidate, modafinil, and amphetamines were mainly used to improve concentration, alertness, endurance, or performance. Cannabis, beta-blockers, and antidepressants, on the other hand, were used to improve inner calm and balance.</Pgraph><Pgraph>A diagnosis of ADHD was reported by 34 people (3.5&#37;). Most of the diagnoses were made in childhood (n&#61;24, 70.6&#37;), and significantly fewer in adolescence and adulthood (n&#61;5, 14.7&#37; each). Approximately one-third of these individuals were taking the prescribed dose of ADHD medication at the time of the study (n&#61;12, 35.3&#37;). These cases were not classified as NE.</Pgraph><Pgraph>Table 3 <ImgLink imgNo="3" imgType="table"/> provides an overview of the positive screenings for ADHD, depression, anxiety, risky alcohol use, and smoking by study. In the overall sample, screening was most frequently positive for risky alcohol use (n&#61;366, 38.2&#37;) and anxiety (n&#61;330, 32.7&#37;). Smoking was rare overall (n&#61;110, 11&#37;). </Pgraph><Pgraph>The mean score for stress in the PSS-10 was M&#61;28.6 (SD&#61;6.8, n&#61;989). The highest values were found among dental students (M&#61;31.7, SD&#61;7.2, n&#61;74), and the lowest values among human medicine students (M&#61;28.0, SD&#61;6.6, n&#61;498). </Pgraph><Pgraph>For the following analyses, only fully completed screening instruments were considered. This reduced the number of cases to 912 (90.3&#37; of the initial sample). ADHD, stress, anxiety, and depression all correlated significantly with each other, with anxiety and stress showing the highest correlation (r&#61;.63). Depression was also significantly related to smoking and risky alcohol consumption (r&#61;.07), and smoking was related to risky alcohol consumption (r&#61;.16). The correlations are shown in table 4 <ImgLink imgNo="4" imgType="table"/>. The correlations between the predictor variables were low overall (r&#60;.70). This indicates that multi-collinearity is not a confounding factor for the following logistic regression analysis.</Pgraph><Pgraph>The results of a binomial regression model for each variable individually and for the combination of all variables are shown in table 5 <ImgLink imgNo="5" imgType="table"/>. The overall binomial regression model was statistically significant, &#967;<Superscript>2</Superscript>(6)&#61;28.40, p&#60;0.001. The odds of NE were 2.49 times higher in smokers than in non-smokers (AOR 2.49, 95&#37; CI 1.50-4.11, p&#60;0.001). Risky alcohol consumption and NE are also positively associated (AOR 1.56, 95&#37; CI 1.05-2.32).</Pgraph></TextBlock>
    <TextBlock language="de" linked="yes" name="3. Ergebnisse">
      <MainHeadline>3. Ergebnisse</MainHeadline><SubHeadline>3.1. Stichprobenbeschreibung</SubHeadline><Pgraph>Von 5564 befragten Studierenden f&#252;llten 1010 den Bogen aus (R&#252;cklauf: 18.2&#37;). Der jeweilige Anteil der Studienf&#228;cher ist in Tabelle 1 <ImgLink imgNo="1" imgType="table"/> dargestellt. Die gr&#246;&#223;te Gruppe (n&#61;594, 61.9&#37;) bildeten die 21-25-j&#228;hrigen (Jahrg&#228;nge 1996-2000). In absteigender H&#228;ufigkeit folgten die Jahrg&#228;nge 1991-1995 (n&#61;225, 23.5&#37;), &#62;2001 (n&#61;82, 8.6&#37;) und &#60;1990 (n&#61;58, 6&#37;). Die Altersverteilung schwankte &#252;ber die Fachbereiche hinweg nur in geringem Ausma&#223;. Die Anzahl der Studierenden im 1. bis zum 4. Semester (n&#61;394, 39&#37;) unterschied sich nicht signifikant von jenen im 5. bis 8. Semester (n&#61;406, 40.2&#37;). Mehr als acht Semester hatten zum Zeitpunkt der Umfrage 20.8&#37; der Teilnehmer&#42;innen (n&#61;210) studiert.</Pgraph><SubHeadline>3.2. Neuroenhancement</SubHeadline><Pgraph>Von den 1010 ausgef&#252;llten Frageb&#246;gen bejahten 125 Studierende NE im Studium praktiziert zu haben. Somit betr&#228;gt die Pr&#228;valenz von NE im Studium 12.4&#37;. Die Pr&#228;valenz von NE w&#228;hrend des Studiums, das Wissen &#252;ber NE und der Anteil der Kommilitonen, von denen bekannt ist, dass sie Substanzen zum NE konsumieren, sind in Tabelle 2 <ImgLink imgNo="2" imgType="table"/> nach Studienfach dargestellt.</Pgraph><Pgraph>Zur Regelm&#228;&#223;igkeit von NE machten 124 Studierende Angaben: Etwa die H&#228;lfte (n&#61;61) verneinte einen regelm&#228;&#223;igen Konsum in den letzten 3 Monaten. Einen fast t&#228;glichen Konsum berichteten 11.3&#37; (n&#61;14), einen w&#246;chentlichen Konsum 15.3&#37; (n&#61;19), einen monatlichen Konsum 9.7&#37; (n&#61;12) der Studierenden. </Pgraph><Pgraph>Fast die H&#228;lfte der Studierenden mit NE-Erfahrung berichtete von NE in den letzten 30 Tagen (n&#61;57). F&#252;r n&#61;25 (20.3&#37;) war NE zwischen 30 Tage und einem Jahr her, f&#252;r ein Drittel war mindestens ein Jahr seit der letzten Nutzung vergangen. Am h&#228;ufigsten wurde die Pr&#252;fungsvorbereitung (n&#61;102, 10.1&#37; der Gesamtstichprobe; 81.6&#37; der Nutzer) als Grund f&#252;r NE angegeben; w&#228;hrend des Semesters war NE seltener (n&#61;50, 5&#37; der Gesamtstichprobe; 40&#37; der Nutzer).</Pgraph><Pgraph>Eine &#228;rztliche Verordnung f&#252;r eine der untersuchten Substanzen hatten 4.7&#37; (n&#61;47) der Teilnehmenden. Von diesen waren 17.0&#37; (n&#61;8) von der verschriebenen Dosis f&#252;r NE-Zwecke abgewichen. Wenn Abweichungen von der verschriebenen Dosis zu NE gez&#228;hlt wurden, stieg die Pr&#228;valenz von NE von 12.4&#37; auf 12.7&#37; (n&#61;128).</Pgraph><Pgraph>Am h&#228;ufigsten wurden Koffeintabletten, Cannabis und Methylphenidat zum NE konsumiert (siehe Abbildung 1 <ImgLink imgNo="1" imgType="figure"/>). Koffeintabletten, Methylphenidat, Modafinil und Amphetamine wurden vorwiegend zur Verbesserung von Konzentration, Wachheit, Ausdauer oder Leistung verwendet. Cannabis, Beta-Blocker und Antidepressiva wurden hingegen zur Verbesserung von innerer Ruhe und Ausgeglichenheit konsumiert.</Pgraph><Pgraph>Eine ADHS-Diagnose gaben 34 Personen (3.5&#37;) an. Die Mehrheit der Diagnosen wurden in der Kindheit (n&#61;24, 70.6&#37;), deutlich weniger im Jugend- und Erwachsenalter gestellt (je n&#61;5, 14.7&#37;). Ungef&#228;hr ein Drittel dieser Personen nahmen zum Zeitpunkt der Studie die verschriebene Dosis ADHS-Medikation ein (n&#61;12, 35.3&#37;). Diese F&#228;lle wurden nicht als NE klassifiziert.</Pgraph><Pgraph>Tabelle 3 <ImgLink imgNo="3" imgType="table"/> gibt einen &#220;berblick &#252;ber die positiven Screenings auf ADHS, Depressivit&#228;t, Angst, riskanten Alkoholkonsum und Rauchen nach Studiengang. In der Gesamtstichprobe war das Screening am h&#228;ufigsten positiv f&#252;r riskanten Alkoholkonsum (n&#61;366, 38.2&#37;) und Angst (n&#61;330, 32.7&#37;). Rauchen war insgesamt (n&#61;110, 11&#37;) selten. </Pgraph><Pgraph>Der Mittelwert f&#252;r Stress im PSS-10 war M&#61;28.6 (SD&#61;6.8, n&#61;989). Die h&#246;chsten Werte wurden bei Zahnmedizinstudierenden gefunden (MW&#61;31.7, SD&#61;7.2, n&#61;74), die niedrigsten bei Humanmedizinstudierenden (MW&#61;28.0, SD&#61;6.6, n&#61;498). </Pgraph><Pgraph>F&#252;r die folgenden Analysen wurden nur vollst&#228;ndig ausgef&#252;llte Screening-Instrumente ber&#252;cksichtigt, was die Anzahl der F&#228;lle auf 912 reduziert (90.3&#37; der Ausgangsstichprobe). ADHS, Stress, Angst, und Depressivit&#228;t korrelierten alle signifikant miteinander, wobei Angst und Stress die h&#246;chste Korrelation aufwiesen (r&#61;.63). Depressivit&#228;t hing zus&#228;tzlich signifikant mit Rauchen und riskantem Alkoholkonsum zusammen (r&#61;.07), Rauchen mit riskantem Alkoholkonsum (r&#61;.16). Die Korrelationen sind in Tabelle 4 <ImgLink imgNo="4" imgType="table"/> dargestellt. Insgesamt waren die Korrelationen zwischen den Pr&#228;diktorvariablen gering (r&#60;.70). Dies deutet darauf hin, dass Multikollinearit&#228;t kein konfundierender Faktor f&#252;r die folgende logistische Regressionsanalyse ist.</Pgraph><Pgraph>Die Ergebnisse eines binomialen Regressionsmodells f&#252;r jede Variable einzeln und die Kombination aller Variablen sind in Tabelle 5 <ImgLink imgNo="5" imgType="table"/> dargestellt. Das gesamte binomiale Regressionsmodell war statistisch signifikant, &#967;<Superscript>2</Superscript>(6)&#61;28.40, p&#60;0.001. Die Wahrscheinlichkeit f&#252;r NE war bei Rauchern 2.49-mal h&#246;her als bei Nichtrauchern (AOR 2.49, 95&#37;-KI 1.50-4.11, p&#60;0.001). Ebenso gab es eine positive Assoziation zwischen riskantem Alkoholkonsum und NE (AOR 1.56, 95&#37;-KI 1.05-2.32).</Pgraph></TextBlock>
    <TextBlock language="en" linked="yes" name="4. Discussion">
      <MainHeadline>4. Discussion</MainHeadline><Pgraph>In this study, NE was examined in a large cohort of students from four disciplines. The sample consisted of an equal number of students from the lower and higher semesters. This means that the preclinical and clinical stages of medical studies are represented in a balanced ratio. Students reported a prevalence of NE of 12.4&#37; during their studies. NE was mainly used in times of exam preparation, with caffeine tablets being consumed most frequently. Authors from Germany and Switzerland also reported similarly high prevalence rates when caffeine tablets are counted as NE <TextLink reference="3"></TextLink>, <TextLink reference="19"></TextLink>. Experience with and knowledge of NE in our study agree well with the existing literature <TextLink reference="20"></TextLink>, <TextLink reference="21"></TextLink>, <TextLink reference="22"></TextLink>, with medical students showing higher knowledge of NE <TextLink reference="5"></TextLink>. The symptom levels of the screenings for ADHD, anxiety, and depression were slightly higher than in the German general population <TextLink reference="23"></TextLink>, <TextLink reference="24"></TextLink>. Even though validated instruments were used, the screening procedure does not yet correspond to a clinical diagnosis, so that these results must be interpreted with caution.</Pgraph><Pgraph>Anxiety, depression, and stress symptoms increase in students during exam periods <TextLink reference="25"></TextLink>. The same applies to the period during the COVID-19 pandemic <TextLink reference="26"></TextLink>: The data collection in winter 2021 coincided with a lockdown phase, when almost all teaching was made online. Another study from the same period found positive anxiety or depression screening in one-fifth of the medical students that were surveyed, which is comparable to our results <TextLink reference="27"></TextLink>. Stress levels were even higher in our sample than in other German students during the pandemic <TextLink reference="28"></TextLink>.</Pgraph><Pgraph>NE was positively associated with symptoms of ADHD. ADHD is an important risk factor for substance abuse, and our finding of higher illicit or non-prescribed substance use in terms of NE in individuals with ADHD symptoms is supported by the literature <TextLink reference="24"></TextLink>. </Pgraph><Pgraph>Links of anxiety, depression, and stress to SD have repeatedly been reported <TextLink reference="2"></TextLink>, <TextLink reference="11"></TextLink>, <TextLink reference="29"></TextLink>. In our study, stress was only weakly but significantly associated with NE, with stress showing high correlations with anxiety and depression. Although we did not have detailed insight into the specific motivation for NE, the associations may suggest that NE is used as a coping strategy to reduce stress by increasing the cognitive performance and attenuating negative emotions. This interpretation could apply to exam phases in particular. On the other hand, stress, depression, and anxiety symptoms could also be a consequence of substance use. This cannot be assessed in a cross-sectional study, however.</Pgraph><Pgraph>In a model with all screening instruments, only correlations of SD with risky alcohol consumption and tobacco use were found. This is similar to the results in other studies <TextLink reference="12"></TextLink>, <TextLink reference="13"></TextLink>. The comparison of the mean values of perceived stress between the groups with and without risky alcohol consumption or between smokers and non-smokers showed no significant differences. This suggests that people who consume alcohol or nicotine are generally more prone to riskier health behaviours.</Pgraph><SubHeadline>4.1. Limitations and strengths</SubHeadline><Pgraph>Our response rate was somewhat lower at 18&#37; than in similar studies (25&#37; <TextLink reference="2"></TextLink> and 22&#37; <TextLink reference="3"></TextLink>). The relatively low response rates could be related to the coincidence with examination times (end of semester). The temporal proximity to the second lockdown of the COVID-19 pandemic is a strength, but also a limitation. The semester was largely held online, and social interaction was reduced to a minimum since December 2020. This may limit comparability with studies from before the pandemic. However, our study provides valuable insights into the consumption behaviour regarding NE, alcohol, and tobacco, as well as into the mental health of students during the pandemic. Nevertheless, the results must be interpreted with caution because some of the predictors were strongly correlated, but none higher than 0.7.</Pgraph><Pgraph>Gender was not allowed to be collected in order to maintain anonymity. Because 72&#37; of the medical students in W&#252;rzburg are female, and because men are more likely to engage in risky health behaviours such as alcohol consumption and smoking <TextLink reference="30"></TextLink>, <TextLink reference="31"></TextLink>, we selected study programmes with a higher proportion of male students (business informatics and business sciences). However, the medical students still represented the largest subgroup, which may have led to an underestimation of the prevalence of NE because medical students consume less. The start page of the survey may have had a strong effect on the selection of participants by making the topic of NE salient, which could have led to an overestimation of NE. Furthermore, we did not control for multiple participation. </Pgraph><Pgraph>The strengths of our survey are the large sample size, especially in view of the fact that this study is the first to address the topic of NE at W&#252;rzburg University. Furthermore, good data quality was achieved through the use of established screening instruments.</Pgraph><SubHeadline>4.2. Conclusion for practice</SubHeadline><Pgraph><UnorderedList><ListItem level="1">NE is a common phenomenon among students. It is associated with mental health problems, although the underlying causal and temporal relations remain unclear.</ListItem><ListItem level="1">NE can be interpreted as a marker for a need for psychosocial support for students.</ListItem><ListItem level="1">Students who are under severe psychological pressure or are at risk could benefit from stress-management programmes, among other things. The programmes should aim to reduce NE by teaching alternative coping strategies.</ListItem><ListItem level="1">The continuation of research on NE in W&#252;rzburg after the pandemic and with an expansion of the sample to other specialist areas is desirable. </ListItem><ListItem level="1">A longitudinal study design would offer the opportunity to investigate changes in NE and mental health during the course of studies.</ListItem></UnorderedList></Pgraph></TextBlock>
    <TextBlock language="de" linked="yes" name="4. Diskussion">
      <MainHeadline>4. Diskussion</MainHeadline><Pgraph>In dieser Studie wurde NE in einer gro&#223;en Kohorte von Studierenden aus vier Fachrichtungen untersucht. Die Stichprobe bestand zu gleichen Teilen aus Studierenden der unteren sowie der h&#246;heren Semester. Somit sind f&#252;r das Medizinstudium Vorklinik und Klinik in einem ausgewogenen Verh&#228;ltnis vertreten. Studierende gaben eine NE Pr&#228;valenz f&#252;r die Zeit des Studiums von 12.4&#37; an. NE wurde vor allem in Zeiten der Pr&#252;fungsvorbereitung eingesetzt, am h&#228;ufigsten wurden Koffeintabletten konsumiert. Auch Autoren aus Deutschland und der Schweiz berichten &#252;ber &#228;hnlich hohe Pr&#228;valenzen, sofern Koffeintabletten zum NE gerechnet werden <TextLink reference="3"></TextLink>, <TextLink reference="19"></TextLink>. Erfahrungen mit und Wissen &#252;ber NE stimmen gut mit der bestehenden Literatur &#252;berein <TextLink reference="20"></TextLink>, <TextLink reference="21"></TextLink>, <TextLink reference="22"></TextLink>, wobei Medizinstudierende h&#246;here Kenntnisse &#252;ber NE aufweisen <TextLink reference="5"></TextLink>. Die Symptomniveaus der Screenings f&#252;r ADHS, Angst, und Depressivit&#228;t waren etwas h&#246;her als in der deutschen Allgemeinbev&#246;lkerung <TextLink reference="23"></TextLink>, <TextLink reference="24"></TextLink>. Trotz des Einsatzes von validierten Instrumenten entspricht ein Screeningverfahren noch keiner klinischen Diagnose, daher m&#252;ssen diese Ergebnisse mit Vorsicht interpretiert werden.</Pgraph><Pgraph>Angst-, Depressions- und Stresssymptome nehmen bei Studierenden in Pr&#252;fungszeiten zu <TextLink reference="25"></TextLink>. Gleiches gilt f&#252;r die Zeit w&#228;hrend der Covid-19-Pandemie <TextLink reference="26"></TextLink>: Die Datenerhebung im Winter 2021 fiel in die Phase des Lockdowns, als nahezu nur Online-Lehre stattfand. Eine andere Studie aus dem gleichen Zeitraum fand bei einem F&#252;nftel der befragten Medizinstudierenden ein positives Angst- oder Depressionsscreening, was vergleichbar mit unseren Ergebnissen ist <TextLink reference="27"></TextLink>. Das Stressniveau war in unserer Stichprobe im Vergleich zu anderen deutschen Studierenden w&#228;hrend der Pandemie sogar h&#246;her <TextLink reference="28"></TextLink>.</Pgraph><Pgraph>NE war positiv mit Symptomen von ADHS assoziiert. ADHS ist ein wichtiger Risikofaktor f&#252;r Substanzmissbrauch, unser Ergebnis eines h&#246;heren Konsums von illegalem oder nicht verschriebenen Substanzen im Sinne von NE bei Personen mit ADHS-Symptomen wird durch die Literatur best&#228;tigt <TextLink reference="24"></TextLink>. </Pgraph><Pgraph>Verbindungen von Angst, Depressivit&#228;t und Stress zu NE sind wiederholt berichtet worden <TextLink reference="2"></TextLink>, <TextLink reference="11"></TextLink>, <TextLink reference="29"></TextLink>. In unserer Studie war Stress nur gering, aber signifikant mit NE assoziiert, wobei Stress hohe Korrelationen mit Angst und Depressivit&#228;t aufwies. Auch wenn wir keinen detaillierten Einblick in die spezifische Motivation f&#252;r NE hatten, k&#246;nnten die Assoziationen darauf hindeuten, dass NE als Bew&#228;ltigungsstrategie eingesetzt wird, um Stress zu reduzieren, indem die kognitive Leistungsf&#228;higkeit erh&#246;ht und negative Emotionen abgeschw&#228;cht werden. Diese Interpretation k&#246;nnte insbesondere f&#252;r Pr&#252;fungsphasen gelten. Andererseits k&#246;nnten Stress, Depression- und Angstsymptome auch eine Folge des Substanzkonsums sein, was durch eine Querschnittstudie allerdings nicht erfasst werden kann.</Pgraph><Pgraph>In einem Modell mit allen Screeninginstrumenten wurden nur noch Zusammenh&#228;nge von NE mit riskantem Alkoholkonsum und Tabakkonsum gefunden, &#228;hnlich wie in anderen Studien <TextLink reference="12"></TextLink>, <TextLink reference="13"></TextLink>. Der Vergleich der Mittelwerte von wahrgenommenem Stress zwischen den Gruppen mit und ohne riskantem Alkoholkonsum bzw. bei Rauchern und Nichtrauchern ergab keine signifikanten Unterschiede. Dies legt nahe, dass Personen, die Alkohol oder Nikotin konsumieren, generell eher zu riskanterem Gesundheitsverhalten neigen.</Pgraph><SubHeadline>4.1. Limitationen und St&#228;rken</SubHeadline><Pgraph>Unser R&#252;cklauf war mit 18&#37; etwas geringer als in &#228;hnlichen Studien (25&#37; <TextLink reference="2"></TextLink> bzw. 22&#37; <TextLink reference="3"></TextLink>). Relativ niedrige R&#252;cklaufquoten k&#246;nnten mit der Koinzidenz zu Pr&#252;fungszeiten (Semesterende) zusammenh&#228;ngen. Eine St&#228;rke, aber auch eine Limitation ist die zeitliche N&#228;he mit dem zweiten Lockdown der COVID-19-Pandemie. Das Semester wurde gr&#246;&#223;tenteils online abgehalten, soziale Interaktion war seit Dezember 2020 auf ein Minimum reduziert. Dies kann die Vergleichbarkeit mit Studien aus der Zeit vor der Pandemie einschr&#228;nken. Die vorliegende Studie liefert aber wertvolle Erkenntnisse &#252;ber das Konsumverhalten bez&#252;glich NE, Alkohol und Tabak sowie die psychische Gesundheit der Studierenden w&#228;hrend der Pandemie. Dennoch m&#252;ssen die Ergebnisse mit Vorsicht interpretiert werden, da zum Teil hohe Korrelationen zwischen den Pr&#228;diktoren vorlagen, wobei keine h&#246;her als 0.7 ausfiel.</Pgraph><Pgraph>Das Geschlecht durfte zur Wahrung der Anonymit&#228;t nicht erhoben werden. Da 72&#37; der Medizinstudierenden in W&#252;rzburg weiblich sind, und das m&#228;nnliche Geschlecht eher mit riskantem Gesundheitsverhalten wie Alkoholkonsum und Rauchen einhergeht <TextLink reference="30"></TextLink>, <TextLink reference="31"></TextLink>, suchten wir Studieng&#228;nge mit einem h&#246;heren Anteil m&#228;nnlicher Studierender aus (Wirtschaftsinformatik und -wissenschaften). Allerdings stellten Medizinstudierende immer noch die gr&#246;&#223;te Untergruppe dar, was aufgrund ihres geringeren Konsums zu einer Untersch&#228;tzung der Pr&#228;valenz von NE gef&#252;hrt haben k&#246;nnte. Die Startseite der Umfrage k&#246;nnte durch Salientmachung des Themas NE stark auf die Selektion der Teilnahme gewirkt haben, was zu einer &#220;bersch&#228;tzung von NE gef&#252;hrt haben k&#246;nnte. Es wurde zudem nicht f&#252;r Mehrfachteilnahmen kontrolliert. </Pgraph><Pgraph>St&#228;rken unserer Erhebung sind der gro&#223;e Stichprobenumfang, vor allem in Anbetracht der Tatsache, dass die vorliegende Arbeit als erste Studie sich dem Thema NE am Hochschulstandort W&#252;rzburg zuwendet. Weiterhin konnte durch die Nutzung etablierter Screeninginstrumente eine gute Datenqualit&#228;t erzielt werden. </Pgraph><SubHeadline>4.2. Fazit f&#252;r die Praxis</SubHeadline><Pgraph><UnorderedList><ListItem level="1">NE ist ein h&#228;ufiges Ph&#228;nomen bei Studierenden und mit psychischen Problemen assoziiert, wobei zugrundeliegende kausale und zeitliche Zusammenh&#228;nge unklar bleiben.</ListItem><ListItem level="1">NE kann als Marker f&#252;r einen Bedarf an psychosozialer Unterst&#252;tzung f&#252;r Studierende interpretiert werden.</ListItem><ListItem level="1">Studierende, die unter starkem psychischen Druck stehen oder gef&#228;hrdet sind, k&#246;nnten u.a. von Stressbew&#228;ltigungsprogrammen profitieren. Diese sollten darauf abzielen, NE durch die Vermittlung alternativer Bew&#228;ltigungsstrategien zu reduzieren.</ListItem><ListItem level="1">Die Fortf&#252;hrung der Forschung zu NE am Standort W&#252;rzburg, nach der Pandemie und mit einer Ausweitung der Stichprobe auf andere Fachbereiche ist w&#252;nschenswert. </ListItem><ListItem level="1">Ein longitudinales Studiendesign, b&#246;te die M&#246;glichkeit die Ver&#228;nderung von NE und psychischer Gesundheit w&#228;hrend des Studiums zu untersuchen </ListItem></UnorderedList></Pgraph></TextBlock>
    <TextBlock language="en" linked="yes" name="Notes">
      <MainHeadline>Notes</MainHeadline><SubHeadline>Authors&#8217; ORCIDs</SubHeadline><Pgraph><UnorderedList><ListItem level="1">Maurice Hajduk: <Hyperlink href="https:&#47;&#47;orcid.org&#47;0009-0005-4538-5316">0009-0005-4538-5316</Hyperlink></ListItem><ListItem level="1">Elena Tiedemann: <Hyperlink href="https:&#47;&#47;orcid.org&#47;0009-0003-2393-6020">0009-0003-2393-6020</Hyperlink></ListItem><ListItem level="1">Marcel Romanos: <Hyperlink href="https:&#47;&#47;orcid.org&#47;0000-0001-7628-8299">0000-0001-7628-8299</Hyperlink></ListItem><ListItem level="1">Anne Simmenroth: <Hyperlink href="https:&#47;&#47;orcid.org&#47;0000-0002-3521-1225">0000-0002-3521-1225</Hyperlink></ListItem></UnorderedList></Pgraph><SubHeadline>First authorship</SubHeadline><Pgraph>The authors Maurice Hajduk and Elena Tiedemann share the first authorship.</Pgraph></TextBlock>
    <TextBlock language="de" linked="yes" name="Anmerkungen">
      <MainHeadline>Anmerkungen</MainHeadline><SubHeadline>ORCIDs der Autor&#42;innen</SubHeadline><Pgraph><UnorderedList><ListItem level="1">Maurice Hajduk: <Hyperlink href="https:&#47;&#47;orcid.org&#47;0009-0005-4538-5316">0009-0005-4538-5316</Hyperlink></ListItem><ListItem level="1">Elena Tiedemann: <Hyperlink href="https:&#47;&#47;orcid.org&#47;0009-0003-2393-6020">0009-0003-2393-6020</Hyperlink></ListItem><ListItem level="1">Marcel Romanos: <Hyperlink href="https:&#47;&#47;orcid.org&#47;0000-0001-7628-8299">0000-0001-7628-8299</Hyperlink></ListItem><ListItem level="1">Anne Simmenroth: <Hyperlink href="https:&#47;&#47;orcid.org&#47;0000-0002-3521-1225">0000-0002-3521-1225</Hyperlink></ListItem></UnorderedList></Pgraph><SubHeadline>Erstautorenschaft</SubHeadline><Pgraph>Die Autor&#42;innen Maurice Hajduk und Elena Tiedemann teilen sich die Erstautorenschaft.</Pgraph></TextBlock>
    <TextBlock language="en" linked="yes" name="Competing interests">
      <MainHeadline>Competing interests</MainHeadline><Pgraph>The authors declare that they have no competing interests. </Pgraph></TextBlock>
    <TextBlock language="de" linked="yes" name="Interessenkonflikt">
      <MainHeadline>Interessenkonflikt</MainHeadline><Pgraph>Die Autor&#42;innen erkl&#228;ren, dass sie keinen Interessenkonflikt im Zusammenhang mit diesem Artikel haben.</Pgraph></TextBlock>
    <References linked="yes">
      <Reference refNo="1">
        <RefAuthor>Franke AG</RefAuthor>
        <RefAuthor>Roser P</RefAuthor>
        <RefAuthor>Lieb K</RefAuthor>
        <RefAuthor>Vollmann J</RefAuthor>
        <RefAuthor>Schildmann J</RefAuthor>
        <RefTitle>Cannabis for Cognitive Enhancement as a New Coping Strategy&#63; Results From a Survey of Students at Four Universities in Germany</RefTitle>
        <RefYear>2016</RefYear>
        <RefJournal>Subst Use Misuse</RefJournal>
        <RefPage>1856-1862</RefPage>
        <RefTotal>Franke AG, Roser P, Lieb K, Vollmann J, Schildmann J. Cannabis for Cognitive Enhancement as a New Coping Strategy&#63; Results From a Survey of Students at Four Universities in Germany. Subst Use Misuse. 2016;51(14):1856-1862. DOI: 10.1080&#47;10826084.2016.1200619</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1080&#47;10826084.2016.1200619</RefLink>
      </Reference>
      <Reference refNo="2">
        <RefAuthor>Middendorff E</RefAuthor>
        <RefAuthor>Poskowsky J</RefAuthor>
        <RefAuthor>Isserstedt W</RefAuthor>
        <RefTitle></RefTitle>
        <RefYear>2012</RefYear>
        <RefBookTitle>Formen der Stresskompensation und Leistungssteigerung bei Studierenden</RefBookTitle>
        <RefPage>118</RefPage>
        <RefTotal>Middendorff E, Poskowsky J, Isserstedt W. Formen der Stresskompensation und Leistungssteigerung bei Studierenden. Hannover: HIS Hochschul-Informations-System GmbH; 2012. p.118.</RefTotal>
      </Reference>
      <Reference refNo="3">
        <RefAuthor>Maier LJ</RefAuthor>
        <RefAuthor>Liechti ME</RefAuthor>
        <RefAuthor>Herzig F</RefAuthor>
        <RefAuthor>Schaub MP</RefAuthor>
        <RefTitle>To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students</RefTitle>
        <RefYear>2013</RefYear>
        <RefJournal>PLoS One</RefJournal>
        <RefPage>e77967</RefPage>
        <RefTotal>Maier LJ, Liechti ME, Herzig F, Schaub MP. To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students. PLoS One. 2013;8(11):e77967. DOI: 10.1371&#47;journal.pone.0077967</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1371&#47;journal.pone.0077967</RefLink>
      </Reference>
      <Reference refNo="4">
        <RefAuthor>Dietz P</RefAuthor>
        <RefAuthor>Quermann A</RefAuthor>
        <RefAuthor>van Poppel MNM</RefAuthor>
        <RefAuthor>Striegel H</RefAuthor>
        <RefAuthor>Schroter H</RefAuthor>
        <RefAuthor>Ulrich R</RefAuthor>
        <RefAuthor>Simon P</RefAuthor>
        <RefTitle>Physical and cognitive doping in university students using the unrelated question model (UQM): Assessing the influence of the probability of receiving the sensitive question on prevalence estimation</RefTitle>
        <RefYear>2018</RefYear>
        <RefJournal>PLoS One</RefJournal>
        <RefPage>e0197270</RefPage>
        <RefTotal>Dietz P, Quermann A, van Poppel MNM, Striegel H, Schroter H, Ulrich R, Simon P. Physical and cognitive doping in university students using the unrelated question model (UQM): Assessing the influence of the probability of receiving the sensitive question on prevalence estimation. PLoS One. 2018;13(5):e0197270. DOI: 10.1371&#47;journal.pone.0197270</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1371&#47;journal.pone.0197270</RefLink>
      </Reference>
      <Reference refNo="5">
        <RefAuthor>Franke AG</RefAuthor>
        <RefAuthor>Bonertz C</RefAuthor>
        <RefAuthor>Christmann M</RefAuthor>
        <RefAuthor>Huss M</RefAuthor>
        <RefAuthor>Fellgiebel A</RefAuthor>
        <RefAuthor>Hildt E</RefAuthor>
        <RefAuthor>Lieb K</RefAuthor>
        <RefTitle>Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany</RefTitle>
        <RefYear>2011</RefYear>
        <RefJournal>Pharmacopsychiatry</RefJournal>
        <RefPage>60-66</RefPage>
        <RefTotal>Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, Hildt E, Lieb K. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry. 2011;44(2):60-66. DOI: 10.1055&#47;s-0030-1268417</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1055&#47;s-0030-1268417</RefLink>
      </Reference>
      <Reference refNo="6">
        <RefAuthor>Gudmundsdottir BG</RefAuthor>
        <RefAuthor>Weyandt L</RefAuthor>
        <RefAuthor>Ernudottir GB</RefAuthor>
        <RefTitle>Prescription Stimulant Misuse and ADHD Symptomatology Among College Students in Iceland</RefTitle>
        <RefYear>2020</RefYear>
        <RefJournal>J Atten Disord</RefJournal>
        <RefPage>384-401</RefPage>
        <RefTotal>Gudmundsdottir BG, Weyandt L, Ernudottir GB. Prescription Stimulant Misuse and ADHD Symptomatology Among College Students in Iceland. J Atten Disord. 2020;24(3):384-401. DOI: 10.1177&#47;1087054716684379</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1177&#47;1087054716684379</RefLink>
      </Reference>
      <Reference refNo="7">
        <RefAuthor>De Bruyn S</RefAuthor>
        <RefAuthor>Wouters E</RefAuthor>
        <RefAuthor>Ponnet K</RefAuthor>
        <RefAuthor>Van Hal G</RefAuthor>
        <RefTitle>Popping smart pills in medical school: Are competition and stress associated with the misuse of prescription stimulants among students&#63;</RefTitle>
        <RefYear>2019</RefYear>
        <RefJournal>Subst Use Misuse</RefJournal>
        <RefPage>1191-1202</RefPage>
        <RefTotal>De Bruyn S, Wouters E, Ponnet K, Van Hal G. Popping smart pills in medical school: Are competition and stress associated with the misuse of prescription stimulants among students&#63; Subst Use Misuse. 2019;54(7):1191-1202. DOI: 10.1080&#47;10826084.2019.1572190</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1080&#47;10826084.2019.1572190</RefLink>
      </Reference>
      <Reference refNo="8">
        <RefAuthor>Benson K</RefAuthor>
        <RefAuthor>Flory K</RefAuthor>
        <RefTitle>Symptoms of Depression and ADHD in Relation to Stimulant Medication Misuse Among College Students</RefTitle>
        <RefYear>2017</RefYear>
        <RefJournal>Subst Use Misuse</RefJournal>
        <RefPage>1937-1945</RefPage>
        <RefTotal>Benson K, Flory K. Symptoms of Depression and ADHD in Relation to Stimulant Medication Misuse Among College Students. Subst Use Misuse. 2017;52(14):1937-1945. DOI: 10.1080&#47;10826084.2017.1318146</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1080&#47;10826084.2017.1318146</RefLink>
      </Reference>
      <Reference refNo="9">
        <RefAuthor>Faraone SV</RefAuthor>
        <RefAuthor>Rostain AL</RefAuthor>
        <RefAuthor>Montano CB</RefAuthor>
        <RefAuthor>Mason O</RefAuthor>
        <RefAuthor>Antshel KM</RefAuthor>
        <RefAuthor>Newcorn JH</RefAuthor>
        <RefTitle>Systematic Review: Nonmedical Use of Prescription Stimulants: Risk Factors, Outcomes, and Risk Reduction Strategies</RefTitle>
        <RefYear>2020</RefYear>
        <RefJournal>J Am Acad Child Adolesc Psychiatry</RefJournal>
        <RefPage>100-112</RefPage>
        <RefTotal>Faraone SV, Rostain AL, Montano CB, Mason O, Antshel KM, Newcorn JH. Systematic Review: Nonmedical Use of Prescription Stimulants: Risk Factors, Outcomes, and Risk Reduction Strategies. J Am Acad Child Adolesc Psychiatry. 2020;59(1):100-112. DOI: 10.1016&#47;j.jaac.2019.06.012</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1016&#47;j.jaac.2019.06.012</RefLink>
      </Reference>
      <Reference refNo="10">
        <RefAuthor>Bagusat C</RefAuthor>
        <RefAuthor>Kunzler A</RefAuthor>
        <RefAuthor>Schlecht J</RefAuthor>
        <RefAuthor>Franke AG</RefAuthor>
        <RefAuthor>Chmitorz A</RefAuthor>
        <RefAuthor>Lieb K</RefAuthor>
        <RefTitle>Pharmacological neuroenhancement and the ability to recover from stress - a representative cross-sectional survey among the German population</RefTitle>
        <RefYear>2018</RefYear>
        <RefJournal>Subst Abuse Treat Prev Policy</RefJournal>
        <RefPage>37</RefPage>
        <RefTotal>Bagusat C, Kunzler A, Schlecht J, Franke AG, Chmitorz A, Lieb K. Pharmacological neuroenhancement and the ability to recover from stress - a representative cross-sectional survey among the German population. Subst Abuse Treat Prev Policy. 2018;13(1):37. DOI: 10.1186&#47;s13011-018-0174-1</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1186&#47;s13011-018-0174-1</RefLink>
      </Reference>
      <Reference refNo="11">
        <RefAuthor>Verdi G</RefAuthor>
        <RefAuthor>Weyandt LL</RefAuthor>
        <RefAuthor>Zavras BM</RefAuthor>
        <RefTitle>Non-Medical Prescription Stimulant Use in Graduate Students: Relationship With Academic Self-Efficacy and Psychological Variables</RefTitle>
        <RefYear>2016</RefYear>
        <RefJournal>J Atten Disord</RefJournal>
        <RefPage>741-753</RefPage>
        <RefTotal>Verdi G, Weyandt LL, Zavras BM. Non-Medical Prescription Stimulant Use in Graduate Students: Relationship With Academic Self-Efficacy and Psychological Variables. J Atten Disord. 2016;20(9):741-753. DOI: 10.1177&#47;1087054714529816</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1177&#47;1087054714529816</RefLink>
      </Reference>
      <Reference refNo="12">
        <RefAuthor>Grant JE</RefAuthor>
        <RefAuthor>Redden SA</RefAuthor>
        <RefAuthor>Lust K</RefAuthor>
        <RefAuthor>Chamberlain SR</RefAuthor>
        <RefTitle>Nonmedical Use of Stimulants Is Associated With Riskier Sexual Practices and Other Forms of Impulsivity</RefTitle>
        <RefYear>2018</RefYear>
        <RefJournal>J Addict Med</RefJournal>
        <RefPage>474-480</RefPage>
        <RefTotal>Grant JE, Redden SA, Lust K, Chamberlain SR. Nonmedical Use of Stimulants Is Associated With Riskier Sexual Practices and Other Forms of Impulsivity. J Addict Med. 2018;12(6):474-480. DOI: 10.1177&#47;1087054714529816</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1177&#47;1087054714529816</RefLink>
      </Reference>
      <Reference refNo="13">
        <RefAuthor>Myrseth H</RefAuthor>
        <RefAuthor>Pallesen S</RefAuthor>
        <RefAuthor>Torsheim T</RefAuthor>
        <RefAuthor>Erevik EK</RefAuthor>
        <RefTitle>Prevalence and correlates of stimulant and depressant pharmacological cognitive enhancement among Norwegian students</RefTitle>
        <RefYear>2018</RefYear>
        <RefJournal>Nordisk Alkohol Nark</RefJournal>
        <RefPage>372-387</RefPage>
        <RefTotal>Myrseth H, Pallesen S, Torsheim T, Erevik EK. Prevalence and correlates of stimulant and depressant pharmacological cognitive enhancement among Norwegian students. Nordisk Alkohol Nark. 2018;35(5):372-387. DOI: 10.1177&#47;1455072518778493</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1177&#47;1455072518778493</RefLink>
      </Reference>
      <Reference refNo="14">
        <RefAuthor>Middendorff E</RefAuthor>
        <RefAuthor>Poskowsky J</RefAuthor>
        <RefAuthor>Isserstedt W</RefAuthor>
        <RefTitle></RefTitle>
        <RefYear>2012</RefYear>
        <RefBookTitle>Formen der Stresskompensation und Leistungssteigerung bei Studierenden</RefBookTitle>
        <RefPage></RefPage>
        <RefTotal>Middendorff E, Poskowsky J, Isserstedt W. Formen der Stresskompensation und Leistungssteigerung bei Studierenden. Hannover: HIS Forum Hochschule; 2012.</RefTotal>
      </Reference>
      <Reference refNo="15">
        <RefAuthor>Kessler RC</RefAuthor>
        <RefAuthor>Adler L</RefAuthor>
        <RefAuthor>Ames M</RefAuthor>
        <RefAuthor>Demler O</RefAuthor>
        <RefAuthor>Faraone S</RefAuthor>
        <RefAuthor>Hiripi E</RefAuthor>
        <RefAuthor>Howes MJ</RefAuthor>
        <RefAuthor>Jin R</RefAuthor>
        <RefAuthor>Secnik K</RefAuthor>
        <RefAuthor>Spencer T</RefAuthor>
        <RefAuthor>Ustun TB</RefAuthor>
        <RefAuthor>Walters EE</RefAuthor>
        <RefTitle>The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population</RefTitle>
        <RefYear>2005</RefYear>
        <RefJournal>Psychol Med</RefJournal>
        <RefPage>245-256</RefPage>
        <RefTotal>Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, Howes MJ, Jin R, Secnik K, Spencer T, Ustun TB, Walters EE. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245-256. DOI: 10.1017&#47;s0033291704002892</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1017&#47;s0033291704002892</RefLink>
      </Reference>
      <Reference refNo="16">
        <RefAuthor>Schneider EE</RefAuthor>
        <RefAuthor>Sch&#246;nfelder S</RefAuthor>
        <RefAuthor>Domke-Wolf M</RefAuthor>
        <RefAuthor>Wessa M</RefAuthor>
        <RefTitle>Measuring stress in clinical and nonclinical subjects using a German adaptation of the Perceived Stress Scale</RefTitle>
        <RefYear>2020</RefYear>
        <RefJournal>Int J Clin Health Psychol</RefJournal>
        <RefPage>173-181</RefPage>
        <RefTotal>Schneider EE, Sch&#246;nfelder S, Domke-Wolf M, Wessa M. Measuring stress in clinical and nonclinical subjects using a German adaptation of the Perceived Stress Scale. Int J Clin Health Psychol. 2020;20(2):173-181. DOI: 10.1016&#47;j.ijchp.2020.03.004</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1016&#47;j.ijchp.2020.03.004</RefLink>
      </Reference>
      <Reference refNo="17">
        <RefAuthor>L&#246;we B</RefAuthor>
        <RefAuthor>Wahl I</RefAuthor>
        <RefAuthor>Rose M</RefAuthor>
        <RefAuthor>Spitzer C</RefAuthor>
        <RefAuthor>Glaesmer H</RefAuthor>
        <RefAuthor>Wingenfeld K</RefAuthor>
        <RefAuthor>Schneider A</RefAuthor>
        <RefAuthor>Br&#228;hler E</RefAuthor>
        <RefTitle>A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population</RefTitle>
        <RefYear>2010</RefYear>
        <RefJournal>J Affect Disord</RefJournal>
        <RefPage>86-95</RefPage>
        <RefTotal>L&#246;we B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, Schneider A, Br&#228;hler E. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122(1-2):86-95. DOI: 10.1016&#47;j.jad.2009.06.019</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1016&#47;j.jad.2009.06.019</RefLink>
      </Reference>
      <Reference refNo="18">
        <RefAuthor>Bush K</RefAuthor>
        <RefAuthor>Kivlahan DR</RefAuthor>
        <RefAuthor>McDonell MB</RefAuthor>
        <RefAuthor>Fihn SD</RefAuthor>
        <RefAuthor>Bradley KA</RefAuthor>
        <RefTitle>The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test</RefTitle>
        <RefYear>1998</RefYear>
        <RefJournal>Arch Intern Med</RefJournal>
        <RefPage>1789-1795</RefPage>
        <RefTotal>Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789-1795. DOI: 10.1001&#47;archinte.158.16.1789</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1001&#47;archinte.158.16.1789</RefLink>
      </Reference>
      <Reference refNo="19">
        <RefAuthor>Franke AG</RefAuthor>
        <RefAuthor>Christmann M</RefAuthor>
        <RefAuthor>Bonertz C</RefAuthor>
        <RefAuthor>Fellgiebel A</RefAuthor>
        <RefAuthor>Huss M</RefAuthor>
        <RefAuthor>Lieb K</RefAuthor>
        <RefTitle>Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany</RefTitle>
        <RefYear>2011</RefYear>
        <RefJournal>Pharmacopsychiatry</RefJournal>
        <RefPage>331-338</RefPage>
        <RefTotal>Franke AG, Christmann M, Bonertz C, Fellgiebel A, Huss M, Lieb K. Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry. 2011;44(7):331-338. DOI: 10.1055&#47;s-0031-1286347</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1055&#47;s-0031-1286347</RefLink>
      </Reference>
      <Reference refNo="20">
        <RefAuthor>Eickenhorst P</RefAuthor>
        <RefAuthor>Vitzthum K</RefAuthor>
        <RefAuthor>Klapp BF</RefAuthor>
        <RefAuthor>Groneberg D</RefAuthor>
        <RefAuthor>Mache S</RefAuthor>
        <RefTitle>Neuroenhancement among German university students: motives, expectations, and relationship with psychoactive lifestyle drugs</RefTitle>
        <RefYear>2012</RefYear>
        <RefJournal>J Psychoactive Drugs</RefJournal>
        <RefPage>418-427</RefPage>
        <RefTotal>Eickenhorst P, Vitzthum K, Klapp BF, Groneberg D, Mache S. Neuroenhancement among German university students: motives, expectations, and relationship with psychoactive lifestyle drugs. J Psychoactive Drugs. 2012;44(5):418-427. DOI: 10.1080&#47;02791072.2012.736845</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1080&#47;02791072.2012.736845</RefLink>
      </Reference>
      <Reference refNo="21">
        <RefAuthor>Heller S</RefAuthor>
        <RefAuthor>Tibubos AN</RefAuthor>
        <RefAuthor>Hoff TA</RefAuthor>
        <RefAuthor>Werner AM</RefAuthor>
        <RefAuthor>Reichel JL</RefAuthor>
        <RefAuthor>M&#252;lder LM</RefAuthor>
        <RefAuthor>Sch&#228;fer M</RefAuthor>
        <RefAuthor>Pfirrmann D</RefAuthor>
        <RefAuthor>Stark B</RefAuthor>
        <RefAuthor>Rigotti T</RefAuthor>
        <RefAuthor>Simon P</RefAuthor>
        <RefAuthor>Beutel ME</RefAuthor>
        <RefAuthor>Letzel S</RefAuthor>
        <RefAuthor>Dietz P</RefAuthor>
        <RefTitle>Potential risk groups and psychological, psychosocial, and health behavioral predictors of pharmacological neuroenhancement among university students in Germany</RefTitle>
        <RefYear>2022</RefYear>
        <RefJournal>Sci Rep</RefJournal>
        <RefPage>937</RefPage>
        <RefTotal>Heller S, Tibubos AN, Hoff TA, Werner AM, Reichel JL, M&#252;lder LM, Sch&#228;fer M, Pfirrmann D, Stark B, Rigotti T, Simon P, Beutel ME, Letzel S, Dietz P. Potential risk groups and psychological, psychosocial, and health behavioral predictors of pharmacological neuroenhancement among university students in Germany. Sci Rep. 2022;12(1):937. DOI: 10.1038&#47;s41598-022-04891-y</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1038&#47;s41598-022-04891-y</RefLink>
      </Reference>
      <Reference refNo="22">
        <RefAuthor>Sattler S</RefAuthor>
        <RefTitle>Cognitive Enhancement in Germany: Prevalence, Attitudes, Moral, Acceptability, Terms, Legal Status, and the Ethics Debate</RefTitle>
        <RefYear>2016</RefYear>
        <RefBookTitle>Cognitive enhancement: ethical and policy implications in international perspectives</RefBookTitle>
        <RefPage>159-180</RefPage>
        <RefTotal>Sattler S. Cognitive Enhancement in Germany: Prevalence, Attitudes, Moral, Acceptability, Terms, Legal Status, and the Ethics Debate. In: Jotterand F, Dubljevic V, editors. Cognitive enhancement: ethical and policy implications in international perspectives. New York: Oxford University Press; 2016. p.159-180. DOI: 10.1093&#47;acprof:oso&#47;9780199396818.001.0001</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1093&#47;acprof:oso&#47;9780199396818.001.0001</RefLink>
      </Reference>
      <Reference refNo="23">
        <RefAuthor>Jacobi F</RefAuthor>
        <RefAuthor>H&#246;fler M</RefAuthor>
        <RefAuthor>Siegert J</RefAuthor>
        <RefAuthor>Mack S</RefAuthor>
        <RefAuthor>Gerschler A</RefAuthor>
        <RefAuthor>Scholl L</RefAuthor>
        <RefAuthor>Busch MA</RefAuthor>
        <RefAuthor>Hapke U</RefAuthor>
        <RefAuthor>Maske U</RefAuthor>
        <RefAuthor>Seiffert I</RefAuthor>
        <RefAuthor>Gaebel W</RefAuthor>
        <RefAuthor>Maier W</RefAuthor>
        <RefAuthor>Wagner M</RefAuthor>
        <RefAuthor>Zielasek J</RefAuthor>
        <RefAuthor>Wittchen HU</RefAuthor>
        <RefTitle>Twelve-month prevalence, comorbidity and correlates of mental disorders in Germany: the Mental Health Module of the German Health Interview and Examination Survey for Adults (DEGS1-MH)</RefTitle>
        <RefYear>2014</RefYear>
        <RefJournal>Int J Methods Psychiatr Res</RefJournal>
        <RefPage>304-319</RefPage>
        <RefTotal>Jacobi F, H&#246;fler M, Siegert J, Mack S, Gerschler A, Scholl L, Busch MA, Hapke U, Maske U, Seiffert I, Gaebel W, Maier W, Wagner M, Zielasek J, Wittchen HU. Twelve-month prevalence, comorbidity and correlates of mental disorders in Germany: the Mental Health Module of the German Health Interview and Examination Survey for Adults (DEGS1-MH). Int J Methods Psychiatr Res. 2014;23(3):304-319. DOI: 10.1002&#47;mpr.1439</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1002&#47;mpr.1439</RefLink>
      </Reference>
      <Reference refNo="24">
        <RefAuthor>Banaschewski T</RefAuthor>
        <RefAuthor>Becker K</RefAuthor>
        <RefAuthor>D&#246;pfner M</RefAuthor>
        <RefAuthor>Holtmann M</RefAuthor>
        <RefAuthor>R&#246;sler M</RefAuthor>
        <RefAuthor>Romanos M</RefAuthor>
        <RefTitle>Attention-Deficit&#47;Hyperactivity Disorder</RefTitle>
        <RefYear>2017</RefYear>
        <RefJournal>Dtsch Arztebl Int</RefJournal>
        <RefPage>149-159</RefPage>
        <RefTotal>Banaschewski T, Becker K, D&#246;pfner M, Holtmann M, R&#246;sler M, Romanos M. Attention-Deficit&#47;Hyperactivity Disorder. Dtsch Arztebl Int. 2017;114(9):149-159. DOI: 10.3238&#47;arztebl.2017.0149</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.3238&#47;arztebl.2017.0149</RefLink>
      </Reference>
      <Reference refNo="25">
        <RefAuthor>Zunhammer M</RefAuthor>
        <RefAuthor>Eberle H</RefAuthor>
        <RefAuthor>Eichhammer P</RefAuthor>
        <RefAuthor>Busch V</RefAuthor>
        <RefTitle>Somatic symptoms evoked by exam stress in university students: the role of alexithymia, neuroticism, anxiety and depression</RefTitle>
        <RefYear>2013</RefYear>
        <RefJournal>PloS One</RefJournal>
        <RefPage>e84911</RefPage>
        <RefTotal>Zunhammer M, Eberle H, Eichhammer P, Busch V. Somatic symptoms evoked by exam stress in university students: the role of alexithymia, neuroticism, anxiety and depression. PloS One. 2013;8(12):e84911. DOI: 10.1371&#47;journal.pone.0084911</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1371&#47;journal.pone.0084911</RefLink>
      </Reference>
      <Reference refNo="26">
        <RefAuthor>Guse J</RefAuthor>
        <RefAuthor>Heinen I</RefAuthor>
        <RefAuthor>Mohr S</RefAuthor>
        <RefAuthor>Bergelt C</RefAuthor>
        <RefTitle>Understanding mental burden and factors associated with study worries among undergraduate medical students during the COVID-19 pandemic</RefTitle>
        <RefYear>2021</RefYear>
        <RefJournal>Front Psychol</RefJournal>
        <RefPage>734264</RefPage>
        <RefTotal>Guse J, Heinen I, Mohr S, Bergelt C. Understanding mental burden and factors associated with study worries among undergraduate medical students during the COVID-19 pandemic. Front Psychol. 2021;12:734264. DOI: 10.3389&#47;fpsyg.2021.734264</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.3389&#47;fpsyg.2021.734264</RefLink>
      </Reference>
      <Reference refNo="27">
        <RefAuthor>Guse J</RefAuthor>
        <RefAuthor>Weegen AS</RefAuthor>
        <RefAuthor>Heinen I</RefAuthor>
        <RefAuthor>Bergelt C</RefAuthor>
        <RefTitle>Mental burden and perception of the study situation among undergraduate students during the COVID-19 pandemic: a cross-sectional study and comparison of dental and medical students</RefTitle>
        <RefYear>2021</RefYear>
        <RefJournal>BMJ Open</RefJournal>
        <RefPage>e054728</RefPage>
        <RefTotal>Guse J, Weegen AS, Heinen I, Bergelt C. Mental burden and perception of the study situation among undergraduate students during the COVID-19 pandemic: a cross-sectional study and comparison of dental and medical students. BMJ Open. 2021;11(12):e054728. DOI: 10.1136&#47;bmjopen-2021-054728</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1136&#47;bmjopen-2021-054728</RefLink>
      </Reference>
      <Reference refNo="28">
        <RefAuthor>Ochnik D</RefAuthor>
        <RefAuthor>Rogowska AM</RefAuthor>
        <RefAuthor>Ku&#347;nierz C</RefAuthor>
        <RefAuthor>Jakubiak M</RefAuthor>
        <RefAuthor>Sch&#252;tz A</RefAuthor>
        <RefAuthor>Held MJ</RefAuthor>
        <RefAuthor>Arzen&#353;ek A</RefAuthor>
        <RefAuthor>Benatov J</RefAuthor>
        <RefAuthor>Berger R</RefAuthor>
        <RefAuthor>Korchagina EV</RefAuthor>
        <RefAuthor>Pavlova I</RefAuthor>
        <RefAuthor>Bla&#382;kov&#225; I</RefAuthor>
        <RefAuthor>Aslan I</RefAuthor>
        <RefAuthor>&#199;&#305;nar O</RefAuthor>
        <RefAuthor>Cuero-Acosta YA</RefAuthor>
        <RefTitle>Mental health prevalence and predictors among university students in nine countries during the COVID-19 pandemic: A cross-national study</RefTitle>
        <RefYear>2021</RefYear>
        <RefJournal>Sci Rep</RefJournal>
        <RefPage>18644</RefPage>
        <RefTotal>Ochnik D, Rogowska AM, Ku&#347;nierz C, Jakubiak M, Sch&#252;tz A, Held MJ, Arzen&#353;ek A, Benatov J, Berger R, Korchagina EV, Pavlova I, Bla&#382;kov&#225; I, Aslan I, &#199;&#305;nar O, Cuero-Acosta YA. Mental health prevalence and predictors among university students in nine countries during the COVID-19 pandemic: A cross-national study. Sci Rep. 2021;11(1):18644. DOI: 10.1038&#47;s41598-021-97697-3</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1038&#47;s41598-021-97697-3</RefLink>
      </Reference>
      <Reference refNo="29">
        <RefAuthor>Jebrini T</RefAuthor>
        <RefAuthor>Manz K</RefAuthor>
        <RefAuthor>Koller G</RefAuthor>
        <RefAuthor>Krause D</RefAuthor>
        <RefAuthor>Soyka M</RefAuthor>
        <RefAuthor>Franke AG</RefAuthor>
        <RefTitle>Psychiatric Comorbidity and Stress in Medical Students Using Neuroenhancers</RefTitle>
        <RefYear>2021</RefYear>
        <RefJournal>Front Psychiatry</RefJournal>
        <RefPage>771126</RefPage>
        <RefTotal>Jebrini T, Manz K, Koller G, Krause D, Soyka M, Franke AG. Psychiatric Comorbidity and Stress in Medical Students Using Neuroenhancers. Front Psychiatry. 2021;12:771126. DOI: 10.3389&#47;fpsyt.2021.771126</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.3389&#47;fpsyt.2021.771126</RefLink>
      </Reference>
      <Reference refNo="30">
        <RefAuthor>Cooke R</RefAuthor>
        <RefAuthor>Beccaria F</RefAuthor>
        <RefAuthor>Demant J</RefAuthor>
        <RefAuthor>Fernandes-Jesus M</RefAuthor>
        <RefAuthor>Fleig L</RefAuthor>
        <RefAuthor>Negreiros J</RefAuthor>
        <RefAuthor>Scholz U</RefAuthor>
        <RefAuthor>de Visser R</RefAuthor>
        <RefTitle>Patterns of alcohol consumption and alcohol-related harm among European university students</RefTitle>
        <RefYear>2019</RefYear>
        <RefJournal>Eur J Public Health</RefJournal>
        <RefPage>1125-9</RefPage>
        <RefTotal>Cooke R, Beccaria F, Demant J, Fernandes-Jesus M, Fleig L, Negreiros J, Scholz U, de Visser R. Patterns of alcohol consumption and alcohol-related harm among European university students. Eur J Public Health. 2019;29(6):1125-9. DOI: 10.1093&#47;eurpub&#47;ckz067</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.1093&#47;eurpub&#47;ckz067</RefLink>
      </Reference>
      <Reference refNo="31">
        <RefAuthor>Kotz D</RefAuthor>
        <RefAuthor>B&#246;ckmann M</RefAuthor>
        <RefAuthor>Kastaun S</RefAuthor>
        <RefTitle>The use of tobacco, e-cigarettes, and methods to quit smoking in Germany: A representative study using 6 waves of data over 12 months (the DEBRA study)</RefTitle>
        <RefYear>2018</RefYear>
        <RefJournal>Dtsch Arztebl Int</RefJournal>
        <RefPage>235-242</RefPage>
        <RefTotal>Kotz D, B&#246;ckmann M, Kastaun S. The use of tobacco, e-cigarettes, and methods to quit smoking in Germany: A representative study using 6 waves of data over 12 months (the DEBRA study). Dtsch Arztebl Int. 2018;115(14):235-242. DOI: 10.3238&#47;arztebl.2018.0235</RefTotal>
        <RefLink>https:&#47;&#47;doi.org&#47;10.3238&#47;arztebl.2018.0235</RefLink>
      </Reference>
    </References>
    <Media>
      <Tables>
        <Table format="png">
          <MediaNo>1</MediaNo>
          <MediaID language="en">1en</MediaID>
          <MediaID language="de">1de</MediaID>
          <Caption language="en"><Pgraph><Mark1>Table 1: Response rate and proportion of total sample by study programme </Mark1></Pgraph></Caption>
          <Caption language="de"><Pgraph><Mark1>Tabelle 1: R&#252;cklauf und Anteil an Gesamtstichprobe nach Studiengang</Mark1></Pgraph></Caption>
        </Table>
        <Table format="png">
          <MediaNo>2</MediaNo>
          <MediaID language="en">2en</MediaID>
          <MediaID language="de">2de</MediaID>
          <Caption language="en"><Pgraph><Mark1>Table 2: Knowledge, awareness of consumption by fellow students, and personal NE by study programme </Mark1></Pgraph></Caption>
          <Caption language="de"><Pgraph><Mark1>Tabelle 2: Wissen, Kenntnis des Konsums durch Kommilitonen und eigenes Neuroenhancement (NE) nach Studiengang</Mark1></Pgraph></Caption>
        </Table>
        <Table format="png">
          <MediaNo>3</MediaNo>
          <MediaID language="en">3en</MediaID>
          <MediaID language="de">3de</MediaID>
          <Caption language="en"><Pgraph><Mark1>Table 3: Positive screenings for ADHD, depression, anxiety, risky alcohol consumption, and smoking by study programme</Mark1> </Pgraph></Caption>
          <Caption language="de"><Pgraph><Mark1>Tabelle 3: Positive Screenings f&#252;r ADHS, Depressivit&#228;t, Angst, riskanten Alkoholkonsum und Rauchen nach Studiengang</Mark1></Pgraph></Caption>
        </Table>
        <Table format="png">
          <MediaNo>4</MediaNo>
          <MediaID language="en">4en</MediaID>
          <MediaID language="de">4de</MediaID>
          <Caption language="en"><Pgraph><Mark1>Table 4: Correlation of the screening instruments (n&#61;912) </Mark1></Pgraph></Caption>
          <Caption language="de"><Pgraph><Mark1>Tabelle 4: Korrelation der Screeninginstrumente (n&#61;912)</Mark1></Pgraph></Caption>
        </Table>
        <Table format="png">
          <MediaNo>5</MediaNo>
          <MediaID language="en">5en</MediaID>
          <MediaID language="de">5de</MediaID>
          <Caption language="en"><Pgraph><Mark1>Table 5: Comparison of the unadjusted and adjusted odds ratios (OR) of the independent variables ADHD, stress, anxiety, depression, risky alcohol consumption, and smoking in relation to the dependent variable NE (N&#61;912)</Mark1></Pgraph></Caption>
          <Caption language="de"><Pgraph><Mark1>Tabelle 5: Vergleich der unadjustierten und adjustierten Odds Ratios (OR) der unabh&#228;ngigen Variablen ADHS, Stress, Angst, Depressivit&#228;t, riskanter Alkoholkonsum und Rauchen in Bezug auf die abh&#228;ngige Variable Neuroenhancement (NE; N&#61;912)</Mark1></Pgraph></Caption>
        </Table>
        <NoOfTables>5</NoOfTables>
      </Tables>
      <Figures>
        <Figure format="png" height="361" width="602">
          <MediaNo>1</MediaNo>
          <MediaID language="en">1en</MediaID>
          <MediaID language="de">1de</MediaID>
          <Caption language="en"><Pgraph><Mark1>Figure 1: Substances used for NE. The percentages are given in relation to the total sample. The frequencies are shown in brackets.</Mark1></Pgraph></Caption>
          <Caption language="de"><Pgraph><Mark1>Abbildung 1: Zum Neuroenhancement verwendete Substanzen; Prozentwerte in Bezug auf Gesamtsichtprobe, H&#228;ufigkeiten in Klammern</Mark1></Pgraph></Caption>
        </Figure>
        <NoOfPictures>1</NoOfPictures>
      </Figures>
      <InlineFigures>
        <NoOfPictures>0</NoOfPictures>
      </InlineFigures>
      <Attachments>
        <NoOfAttachments>0</NoOfAttachments>
      </Attachments>
    </Media>
  </OrigData>
</GmsArticle>